ADMA Biologics Statistics
Total Valuation
ADMA Biologics has a market cap or net worth of $3.05 billion. The enterprise value is $3.14 billion.
| Market Cap | 3.05B |
| Enterprise Value | 3.14B |
Important Dates
The next estimated earnings date is Wednesday, August 7, 2024, after market close.
| Earnings Date | Aug 7, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
ADMA Biologics has 231.81 million shares outstanding. The number of shares has increased by 6.53% in one year.
| Shares Outstanding | 231.81M |
| Shares Change (YoY) | +6.53% |
| Shares Change (QoQ) | +4.61% |
| Owned by Insiders (%) | 2.59% |
| Owned by Institutions (%) | 79.05% |
| Float | 227.76M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | 32.05 |
| PS Ratio | 10.77 |
| Forward PS | 7.95 |
| PB Ratio | 19.85 |
| P/FCF Ratio | 189.12 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 111.87, with an EV/FCF ratio of 194.49.
| EV / Earnings | n/a |
| EV / Sales | 11.08 |
| EV / EBITDA | 111.87 |
| EV / EBIT | 159.81 |
| EV / FCF | 194.49 |
Financial Position
The company has a current ratio of 5.21, with a Debt / Equity ratio of 0.86.
| Current Ratio | 5.21 |
| Quick Ratio | 1.79 |
| Debt / Equity | 0.86 |
| Debt / EBITDA | 4.70 |
| Debt / FCF | 8.18 |
| Interest Coverage | 0.87 |
Financial Efficiency
Return on equity (ROE) is -2.50%.
| Return on Equity (ROE) | -2.50% |
| Return on Assets (ROA) | -1.10% |
| Return on Capital (ROIC) | n/a |
| Revenue Per Employee | $453,808 |
| Profits Per Employee | -$5,840 |
| Employee Count | 624 |
| Asset Turnover | 0.83 |
| Inventory Turnover | 1.00 |
Taxes
In the past 12 months, ADMA Biologics has paid $595,000 in taxes.
| Income Tax | 595,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +238.30% in the last 52 weeks. The beta is 0.55, so ADMA Biologics's price volatility has been lower than the market average.
| Beta (5Y) | 0.55 |
| 52-Week Price Change | +238.30% |
| 50-Day Moving Average | 11.12 |
| 200-Day Moving Average | 6.58 |
| Relative Strength Index (RSI) | 63.87 |
| Average Volume (20 Days) | 3,448,704 |
Short Selling Information
The latest short interest is 8.28 million, so 3.57% of the outstanding shares have been sold short.
| Short Interest | 8.28M |
| Short Previous Month | 7.27M |
| Short % of Shares Out | 3.57% |
| Short % of Float | 3.63% |
| Short Ratio (days to cover) | 2.48 |
Income Statement
In the last 12 months, ADMA Biologics had revenue of $283.18 million and -$3.64 million in losses. Loss per share was -$0.02.
| Revenue | 283.18M |
| Gross Profit | 111.54M |
| Operating Income | 44.27M |
| Pretax Income | -3.05M |
| Net Income | -3.64M |
| EBITDA | 28.04M |
| EBIT | 19.63M |
| Loss Per Share | -$0.02 |
Balance Sheet
The company has $45.33 million in cash and $131.94 million in debt, giving a net cash position of -$86.62 million or -$0.37 per share.
| Cash & Cash Equivalents | 45.33M |
| Total Debt | 131.94M |
| Net Cash | -86.62M |
| Net Cash Per Share | -$0.37 |
| Equity (Book Value) | 153.71M |
| Book Value Per Share | 0.66 |
| Working Capital | 223.33M |
Cash Flow
In the last 12 months, operating cash flow was $21.30 million and capital expenditures -$5.17 million, giving a free cash flow of $16.13 million.
| Operating Cash Flow | 21.30M |
| Capital Expenditures | -5.17M |
| Free Cash Flow | 16.13M |
| FCF Per Share | $0.07 |
Margins
Gross margin is 39.39%, with operating and profit margins of 15.63% and -1.29%.
| Gross Margin | 39.39% |
| Operating Margin | 15.63% |
| Pretax Margin | -1.08% |
| Profit Margin | -1.29% |
| EBITDA Margin | 9.90% |
| EBIT Margin | 6.93% |
| FCF Margin | 5.70% |
Dividends & Yields
ADMA Biologics does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -6.53% |
| Shareholder Yield | -6.53% |
| Earnings Yield | -0.12% |
| FCF Yield | 0.53% |
Analyst Forecast
The average price target for ADMA Biologics is $12.25, which is -6.91% lower than the current price. The consensus rating is "Strong Buy".
| Price Target | $12.25 |
| Price Target Difference | -6.91% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 4 |
| Revenue Growth Forecast (5Y) | 16.53% |
| EPS Growth Forecast (5Y) | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
ADMA Biologics has an Altman Z-Score of 9.09 and a Piotroski F-Score of 5.
| Altman Z-Score | 9.09 |
| Piotroski F-Score | 5 |